Latest Ratios: P/E Ratio -3.2x · EV/EBITDA N/A · ROE -310.7%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $223M | $230M | $330M | $324M | $637M | $1.1B | $199M | $173M | $408M | $308M | $238M |
| Enterprise Value | $224M | $231M | $316M | $296M | $676M | $1.2B | $243M | $196M | $322M | $317M | $244M |
| P/E Ratio → | -3.21 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.32 | 6.53 | 14.67 | 14.46 | 38.85 | 82.46 | 40.16 | 8.12 | 21.56 | 48.41 | 717.72 |
| P/B Ratio | 3.64 | 3.77 | — | 9.04 | — | — | — | — | 5.72 | 42.45 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.56 | 14.07 | 13.21 | 41.27 | 84.71 | 49.19 | 9.18 | 17.02 | 49.71 | 736.30 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 4.21 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 44.7% | 44.7% | 2.4% | 13.8% | 16.6% | -5.9% | -350.9% | -91.3% | -43.1% | -53.1% | -98.8% |
| Operating Margin | -193.8% | -193.8% | -333.0% | -337.7% | -418.7% | -418.1% | -1598.9% | -613.4% | -463.1% | -883.6% | -12781.0% |
| Net Profit Margin | -196.0% | -196.0% | -349.8% | -269.7% | 867.2% | -2211.9% | -3539.5% | -542.5% | -496.9% | -927.4% | -13231.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -310.7% | -310.7% | -817.2% | -363.6% | — | — | — | -369.1% | -239.3% | -4945.7% | — |
| ROA | -61.0% | -61.0% | -65.9% | -38.2% | 75.5% | -257.6% | -207.6% | -78.9% | -91.3% | -173.3% | -316.5% |
| ROIC | -322.6% | -322.6% | — | -252.7% | — | — | — | — | -12643.6% | -500.0% | — |
| ROCE | -83.6% | -83.6% | -82.0% | -56.6% | -42.0% | -57.2% | -623.7% | -190.5% | -113.8% | -336.7% | -964.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.68 | 0.68 | — | 1.33 | — | — | — | — | 0.72 | 3.37 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.01 | — | -0.78 | — | — | — | — | -1.20 | 1.15 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -12.96 | -12.96 | -8.32 | -4.44 | 8.60 | -17.09 | -9.83 | -6.63 | -10.35 | -18.07 | -26.42 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.83 | 4.83 | 2.35 | 7.53 | 5.12 | 7.85 | 1.82 | 1.01 | 5.47 | 1.94 | 1.84 |
| Quick Ratio | 4.55 | 4.55 | 2.24 | 7.03 | 4.89 | 7.51 | 1.50 | 0.87 | 5.12 | 1.81 | 1.80 |
| Cash Ratio | 3.87 | 3.87 | 1.92 | 6.34 | 4.58 | 7.06 | 1.08 | 0.76 | 4.74 | 1.58 | 1.75 |
| Asset Turnover | — | 0.28 | 0.22 | 0.16 | 0.09 | 0.07 | 0.14 | 0.16 | 0.12 | 0.14 | 0.01 |
| Inventory Turnover | 2.91 | 2.91 | 4.96 | 2.20 | 1.87 | 2.29 | 4.23 | 2.41 | 2.64 | 3.26 | 1.38 |
| Days Sales Outstanding | — | 128.68 | 131.22 | 107.54 | 62.07 | 64.49 | 220.22 | 179.68 | 136.96 | 193.93 | 275.95 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $42M | $31M | $28M | $31M | $21M | $11M | $9M | $8M | $6M | $4M |
High cash burn rate
As reported in recent financial statements, SENS trades at a price-to-sales multiple of 6.78, a valuation that appears to reflect investor optimism regarding the 365-day sensor pipeline rather than current fundamental performance, especially when contrasted with the more mature, profitable profiles of industry incumbents like Dexcom.
The current P/S multiple suggests the market is pricing in significant future growth, yet this valuation remains disconnected from the company's persistent negative earnings and lack of positive EBITDA. Investors should monitor whether this premium can be sustained if clinical milestones are delayed or if the commercial pull-through fails to accelerate beyond current levels.
Based on the provided ten-quarter data, SENS has consistently generated negative ROIC, with a recent figure of -43.7% in 2026Q1, indicating that the company is currently destroying rather than compounding invested capital as it struggles to achieve the necessary scale for its implantable CGM technology.
The persistent negative return on capital suggests that the high fixed-cost base required for R&D and clinical trials is not yet being offset by sufficient gross profit generation. Without a clear path to positive operating margins, the company appears to be in a cycle of capital consumption that necessitates frequent external financing.
According to the latest quarterly figures, the company's cash conversion cycle reached 179 days in 2026Q1, a significant increase from previous periods that highlights the operational challenges of managing inventory and receivables within a specialized medical device distribution model involving third-party partners like Ascensia.
The elevated days inventory outstanding (DIO) of 142 days suggests potential inefficiencies in inventory management or a slower-than-expected sell-through rate for the Eversense system. This working capital drag further exacerbates the company's liquidity constraints, as cash remains tied up in the supply chain rather than funding core growth initiatives.
As indicated by the 2026Q1 debt-to-equity ratio of 1.26, SENS has increasingly relied on debt financing to bridge its operational funding gap, a trend that warrants caution given the company's inability to generate positive interest coverage in any of the last ten reported quarters.
The reliance on debt in a pre-profit state creates significant refinancing risk, particularly if the company's cash runway continues to shorten. The lack of positive EBITDA means that debt service is entirely dependent on external capital raises, which may lead to further shareholder dilution if the company cannot reach cash-flow neutrality.
Investors frequently misapply the price-to-sales ratio to SENS, failing to account for the fact that a significant portion of reported revenue may represent sell-in to distributors rather than actual patient adoption, thereby obscuring the true underlying demand for the Eversense CGM system.
Relying on P/S multiples ignores the critical 'procedure friction' and the high cost of customer acquisition inherent in an implantable device model. A more appropriate metric for this business would be 'cash burn per active user' or 'customer acquisition cost relative to lifetime value,' which would better reflect the economic reality of the company's commercialization strategy.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SENS stock.
Senseonics Holdings, Inc.'s current P/E ratio is -3.2x. This places it at the 50th percentile of its historical range.
Senseonics Holdings, Inc.'s return on equity (ROE) is -310.7%. The historical average is -351.9%.
Based on historical data, Senseonics Holdings, Inc. is trading at a P/E of -3.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Senseonics Holdings, Inc. has 44.7% gross margin and -193.8% operating margin.